AINOS INC (AIMD)
NASDAQInformation TechnologyBiotechnologySnapshot 2026-09-04
$1.60+2.56%
Close 2026-09-04 · 1-day change
NASDAQInformation TechnologyBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AIMD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Advance commercialization and deployment of AI Nose in semiconductor manufacturing, healthcare infrastructure, robotics, and industrial markets.
Stated as a priority in 2 of last 2 quarters. Revenue declined slightly from $161K in 2026-Q1 to $152K in 2026-Q2 amid ongoing commercialization. Management highlights steady expansion of AI Nose deployments and accumulation of 613 million smell data records since December 2025. The trajectory shows persistent execution focus but limited revenue growth so far.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Information Technology names rated weak grew net income 47% of the time over the next year (vs 59% for the rest of the cohort, n=6360).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Continued executing commercialization roadmap by expanding AI Nose deployments across semiconductor manufacturing, industrial infrastructure, healthcare, and robotics environments.”
“Continued executing commercialization priorities for AI Nose across industrial infrastructure environments and expanded deployment into healthcare infrastructure settings.”
Continue development and refinement of Smell ID datasets and Smell Language Model through deployments and pilot activities.
Stated as a priority in 2 of last 2 quarters. Management emphasizes ongoing expansion and refinement of Smell ID datasets and Smell Language Model capabilities through deployments and pilots. No direct financial metrics quantify progress, indicating a focus on product development with steady but qualitative advancement.
“Continued development of Smell ID datasets and smell language model capabilities using deployment and pilot data.”
“Continued to expand Smell ID datasets and refine Smell Language Model through deployment and pilot activities.”
Control operating expenses to support commercialization efforts and improve financial management.
Stated as a priority in 2 of last 2 quarters. Operating expenses declined 30% year-over-year to $2.28 million in 2026-Q1 but rose to $4.40 million in 2026-Q2. Management reiterates commitment to expense discipline alongside commercialization. The trajectory shows mixed progress with recent expense increase despite prior reduction.
“Committed to disciplined capital allocation and financial management while supporting commercialization and technology development.”
“Maintained operating discipline as we advanced commercialization activities; operating expenses declined approximately 30% year-over-year to $2.28 million.”
Improve financial stability through financing arrangements and disciplined capital management.
Stated as a priority in 2 of last 2 quarters. Cash and cash equivalents rose from $417K in 2025-Q4 to $1.42M in 2026-Q2, supported by a NT$90 million (approx. US$2.8 million) financing. Convertible notes payable increased to $11M by 2026-Q2. Management maintains focus on capital discipline and liquidity strengthening, showing delivering trajectory.
“Committed to disciplined capital allocation and financial management while supporting commercialization and technology development.”
“Strengthened balance sheet and liquidity position through NT$90 million (approx. US$2.8 million) financing arrangement.”
Over the trailing year it converted 0.34x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
10 material management or governance events in the past 24 months, led by M&A activity. Historically, Information Technology names rated neutral grew net income 60% of the time over the next year (vs 57% for the rest of the cohort, n=3673).
Not investment advice. As of 2026-09-04.